Breaking Finance News

Depomed Inc (NASDAQ:DEPO) stock price target increased to $27.00, issued a research note today by Mizuho

Boasting a price of $25.58, Depomed Inc (NASDAQ:DEPO) traded 2.44% higher on the day. With the last stock price close up 33.10% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. DEPO has recorded a 50-day moving average of $22.17 and a 200-day moving average of $19.22. 3,741,214 shares of the stock were exchanged, up from an average trading volume of 1,365,000

Reporting a potential upside of 0.06%, Mizuho upped the price target of Depomed Inc (NASDAQ:DEPO) to $27.00

On 9/19/2016, Mizuho Securities released a statement about Depomed Inc (NASDAQ:DEPO) upped the target price from $23.00 to $27.00 that suggested an upside of 0.11%.

See Chart Below

Depomed Inc (NASDAQ:DEPO)

Depomed Inc has a 52 week low of $12.25 and a 52 week high of $27.02 The company’s market cap is presently $0.

A total of 11 equity analysts have released a ratings update on DEPO. Two equity analysts rating the company a strong buy, nine equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $23.73.

Brief Synopsis About Depomed Inc (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *